Elsevier

The Lancet

Volume 370, Issue 9605, 22 December 2007–4 January 2008, Pages 2082-2084
The Lancet

Comment
Clinical update: treating osteoarthritis

https://doi.org/10.1016/S0140-6736(07)61879-0Get rights and content

First page preview

First page preview
Click to open first page preview

References (20)

  • PA Dieppe et al.

    Pathogenesis and management of pain in osteoarthritis

    Lancet

    (2005)
  • FK Chan et al.

    Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial

    Lancet

    (2007)
  • E Roddy et al.

    Changing life-styles and osteoarthritis: what is the evidence?

    Best Pract Res Clin Rheumatol

    (2006)
  • KM Jordan et al.

    EULAR Recommendations 2003: an evidence based medicine approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

    Ann Rheum Dis

    (2003)
  • W Zhang et al.

    EULAR evidence based recommendations for the management of hip osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

    Ann Rheum Dis

    (2005)
  • W Zhang et al.

    EULAR evidence based recommendations for the management of hand osteoarthritis—report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

    Ann Rheum Dis

    (2007)
  • W Zhang et al.

    OARSI Recommendations for the management of hip and knee osteoarthritis. Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence

    Osteoarthritis Cartilage

    (2007)
  • Osteoarthritis: draft guidance for consultation

  • JB Moseley et al.

    A controlled trial of arthroscopic surgery for osteoarthritis of the knee

    N Engl J Med

    (2002)
  • S Herrlin et al.

    Arthroscopic or conservative treatment of degenerative meniscal tears: a prospective randomized trial

    Knee Surg Sports Traumatol

    (2007)
There are more references available in the full text version of this article.

Cited by (106)

  • Enhancing the chondrogenic potential of chondrogenic progenitor cells by deleting RAB5C

    2021, iScience
    Citation Excerpt :

    The disease is characterized by the degradation of the articular cartilage, which results in impaired joint functionality (Felson, 2006). Current therapies provide symptomatic relief but are unable to cure the disease, and patients eventually require total joint replacement (Lohmander and Roos, 2007). The search for new OA treatment options focuses on regenerative cell therapies, among others modalities (Brittberg et al., 1994; Schminke and Miosge, 2014).

  • Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration

    2021, Biomaterials
    Citation Excerpt :

    Deterioration of the OA condition can only be treated with surgeries, including total joint replacement by a prosthetic joint [7,8]. Cell therapies represent a new generation of OA treatment [12,13]. Options include transplanting plugs of cartilage isolated from non-weight-bearing areas to the defect site (mosaicplasty) [7,14], autologous chondrocyte transplantation using cultured chondrocytes isolated from a cartilage biopsy [7,8], and inducing regeneration of a fibrous type of cartilage by drilling through the subchondral bone to release marrow elements [8,14].

View all citing articles on Scopus
View full text